ERBB2 and breast carcinoma: For instance, in the context of PRS5, a breast cancer subtype analyzed using the I-SPY2 cohort, around 50% of the “HER2−/immune−/DRD+” (N = 78) cluster is further classified into “immune+/replication+” within I2G-C.